Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT00337168 Completed - Leukemia Clinical Trials

S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: October 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving cytarabine together with clofarabine works in treating patients with relapsed or refractory acute lymphoblastic leukemia.

NCT ID: NCT00334074 Completed - Clinical trials for Myelodysplastic Syndromes

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.

NCT ID: NCT00333840 Completed - Clinical trials for Chronic Myelogenous Leukemia

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Start date: June 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.

NCT ID: NCT00331513 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

Start date: March 2006
Phase: Phase 1
Study type: Interventional

This randomized phase I trial is studying the side effects and best dose of vorinostat when given together with idarubicin in treating patients with relapsed or refractory leukemia or myelodysplastic syndromes. Drugs used in chemotherapy, such as vorinostat and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with idarubicin may kill more cancer cells.

NCT ID: NCT00328198 Completed - Clinical trials for B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATH, MabCampath) as therapy for patients with relapsed or refractory B-CLL who have been previously treated.

NCT ID: NCT00327678 Completed - Clinical trials for Leukemia, Lymphocytic

Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Start date: May 2006
Phase: Phase 3
Study type: Interventional

This study is a multicenter trial of treatment for young ALL patients. All ALL patients will receive the same steroid pre-phase in order to evaluate sensitivity or resistance. Then, patients will be included into 3 specific trials according to biological features (immunophenotype, cytogenetics, and molecular biology). Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2005: - T ALL or B ALL non Ph (N=810 patients planned). - GRAALL 2005 R: B ALL non Ph CD20+ (N=220 patients planned). - GRAAPH 2005: ALL Ph+ (N=270 patients planned)

NCT ID: NCT00324779 Completed - Lymphoma Clinical Trials

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

Start date: March 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Giving rituximab before chemotherapy may be an effective treatment for B-cell non-Hodgkin's lymphoma or B-cell acute lymphoblastic leukemia. PURPOSE: This phase II trial is studying how well rituximab works in treating young patients who are planning to receive chemotherapy for B-cell non-Hodgkin's lymphoma or B-cell acute lymphoblastic leukemia.

NCT ID: NCT00324220 Completed - Clinical trials for Myelodysplastic Syndrome

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Start date: January 2006
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.

NCT ID: NCT00324194 Completed - Leukemia Clinical Trials

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Start date: February 2005
Phase: Phase 1
Study type: Interventional

In this study, MGCD0103, a new anticancer drug under investigation, is given twice weekly to patients with leukemia or myelodysplastic syndromes.

NCT ID: NCT00324129 Completed - Leukemia Clinical Trials

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Start date: February 2005
Phase: Phase 1
Study type: Interventional

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with leukemia or myelodysplastic syndromes.